DORA Medications for Insomnia
Yes, you're thinking of Dual Orexin Receptor Antagonists (DORAs) - the main FDA-approved medications in this class are suvorexant, lemborexant, and daridorexant, all effective for treating insomnia.
Available DORA Medications
The American Academy of Sleep Medicine guidelines specifically recommend suvorexant as a treatment option for sleep maintenance insomnia 1. However, newer DORAs have since been approved and studied:
FDA-Approved DORAs:
- Suvorexant - doses of 10,15/20, and 20 mg 1
- Lemborexant - particularly effective with relative selectivity for orexin receptor type 2 2
- Daridorexant - recently approved with promising efficacy 3
- Vornorexant - newest agent with notably short half-life comparable to zolpidem 4, 5
How DORAs Work
These medications block orexin receptors (OX1 and OX2) that promote wakefulness. By antagonizing these receptors, DORAs facilitate natural sleep without forcing sedation like traditional hypnotics 4, 6.
Clinical Evidence
Meta-analyses demonstrate that suvorexant, lemborexant, and daridorexant improve both subjective and objective sleep measures with small to moderate effect sizes 7, 6. Specifically:
- All efficacy outcomes (sleep latency, total sleep time, wake after sleep onset, sleep quality) significantly improved compared to placebo 6
- Lemborexant often ranks highest among hypnotics in network meta-analyses 2
- Long-term use (≥6 months) shows sustained improvements in sleep parameters 8
Safety Profile Advantages
DORAs offer significant safety advantages over traditional benzodiazepines and Z-drugs:
- Minimal next-morning residual effects despite long terminal half-lives 2
- Low risk of dependence, tolerance, or withdrawal symptoms 2, 6
- Uncommon cognitive impairment or driving deficits 2
- Falls and fractures comparable to placebo 2
- Safe in older adults and patients with obstructive sleep apnea or COPD 2, 3
Common Adverse Events:
The most frequent side effect is somnolence, with occasional reports of excessive daytime sleepiness, fatigue, dry mouth, and abnormal dreams 6. Serious adverse events like hallucinations, suicidal ideation, and motor vehicle accidents do not differ from placebo 6.
Clinical Positioning
According to 2017 AASM guidelines, suvorexant receives a weak recommendation for sleep maintenance insomnia, with low-quality evidence showing benefits outweigh harms 1. However, this predates the approval and extensive study of lemborexant and daridorexant.
Recent evidence (2025-2026) suggests DORAs, particularly lemborexant, are more effective and safer than GABAA receptor modulators (benzodiazepines/Z-drugs) for both short and long-term insomnia treatment 9. They better preserve natural sleep architecture and show fewer contraindications 9.